Evidence map›Paper›PMID 29375202›Full record

ReviewWorld journal of gastroenterology2018

Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.

Antonio Facciorusso

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07657897 (The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection), which is not on this map. Cited by 69 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 3 pooled it
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07657897 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection

TypeinterventionalSponsorIuliu Hatieganu University of Medicine and PharmacyRan2024 to 2026Enrolled100ConditionsHepato Cellular Carcinoma (HCC), Sedation and Analgesia, Ablation TechniquesArmsSedation using combination of Propofol and Fentanyl., Sedation using combination of Propofol and Fentanyl and lidocaine
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Conventional and drug‑eluting bead transarterial chemoembolization in patients with inoperable intrahepatic cholangiocarcinoma: a meta‑analysis.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024
    Pooled it
  3. Pooled it
  4. Trial
  5. Comparison of CalliSpheresRadiology and oncology · 2023
    Trial
  6. Observational
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Regional chemotherapy for uveal melanoma liver metastases.International journal of ophthalmology · 2023
    Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Antonio FacciorussoGastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia 71122, Italy. antonio.facciorusso@virgilio.it.
Creative Research Enterprises (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transarterial chemoembolization (TACE) represents the current gold standard for hepatocellular carcinoma (HCC) patients in intermediate stage. Conventional TACE (cTACE) is performed with the injection of an emulsion of a chemotherapeutic drug with lipiodol into the artery feeding the tumoral nodules, followed by embolization of the same vessel to obtain a synergistic effect of drug cytotoxic activity and ischemia. Aim of this review is to summarize the main characteristics of drug-eluting beads (DEB)-TACE and the clinical results reported so far in the literature. A literature search was conducted using PubMed until June 2017. In order to overcome the drawbacks of cTACE, namely lack of standardization and unpredictability of outcomes, non-absorbable embolic microspheres charged with cytotoxic agents (DEBs) have been developed. DEBs are able to simultaneously exert both the therapeutic components of TACE, either drug-carrier function and embolization, unlike cTACE in which applying the embolic agent is a second moment after drug injection. This way, risk of systemic drug release is minimal due to both high-affinity carrier activity of DEBs and absence of a time interval between injection and embolization. However, despite promising results of preliminary studies, clear evidence of superiority of DEB-TACE over cTACE is still lacking. A number of novel technical devices are actually in development in the field of loco-regional treatments for HCC, but only a few of them have entered the clinical arena. In absence of well-designed randomized-controlled trials, the decision on whether use DEB-TACE or cTACE is still controversial.

Indexed as

Drug CarriersAnimalsAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticDiffusion of InnovationHumansInjections, Intra-ArterialLiver NeoplasmsTreatment OutcomeAntineoplastic AgentsDrug CarriersConventionalDoxorubicinEmbolizationHepatocarcinomaLiver cancerSurvival

Identifiers

PMID29375202
PMCPMC5768935
OpenAlexW2783948736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.